Travere Therapeutics (TVTX) EBIT Margin (2014 - 2026)
Travere Therapeutics (TVTX) posted EBIT Margin of 29.02% for Q1 2026, down 414.79% on a QoQ basis from 9.22% in Q4 2025, and up 2319.0% year-over-year from 1.2% in Q1 2025.
Travere Therapeutics (TVTX) EBIT Margin (2014 - 2026) Analysis & Trends
Travere Therapeutics' EBIT Margin history runs 13 years deep, the most recent figure standing at 29.02% for Q1 2026.
- Quarterly EBIT Margin rose 2319.0% year-over-year to 29.02% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 81.41% (up 16450.0% YoY) and the FY2025 annual result came in at 675.53%, down 53665.0% from the prior year.
- EBIT Margin was 29.02% for Q1 2026 at Travere Therapeutics, down from 9.22% in the prior quarter.
- Across five years, EBIT Margin topped out at 62.33% in Q3 2025 and bottomed at 336.53% in Q1 2024.
- A 5-year average of 171.83% and a median of 209.13% in 2023 frame the typical range for EBIT Margin.
- Annual changes were most pronounced in 2022 — EBIT Margin plunged 34914 bps — and 2025, when it surged 28432 bps.
- Travere Therapeutics' EBIT Margin stood at 295.52% in 2022, then increased by 29 bps to 209.13% in 2023, then soared by 61 bps to 81.21% in 2024, then jumped by 111 bps to 9.22% in 2025, then slumped by 415 bps to 29.02% in 2026.
- Business Quant data shows TVTX's EBIT Margin at 29.02% in Q1 2026, 9.22% in Q4 2025, and 62.33% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 16.51% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 38.10% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 17.83% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 31.68% |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Travere Therapeutics | 5.21 Bn | 5.21 Bn | 125.25 Mn | -29.02% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -29.02% |
| Dec 31, 2025 | 9.22% |
| Sep 30, 2025 | 62.33% |
| Jun 30, 2025 | -11.05% |
| Mar 31, 2025 | -52.21% |
| Dec 31, 2024 | -81.21% |
| Sep 30, 2024 | -89.27% |
| Jun 30, 2024 | -125.11% |
| Mar 31, 2024 | -336.53% |
| Dec 31, 2023 | -209.13% |
| Sep 30, 2023 | -249.59% |
| Jun 30, 2023 | -322.87% |
| Mar 31, 2023 | -315.23% |
| Dec 31, 2022 | -295.52% |
| Sep 30, 2022 | -294.23% |
| Jun 30, 2022 | -274.24% |
| Mar 31, 2022 | -307.45% |
| Dec 31, 2021 | 53.62% |
| Sep 30, 2021 | -46.49% |
| Jun 30, 2021 | -64.66% |